Search research articles
Contact Us
Filters
Showing results (71-80 of 102) with videos related to
Page
of 11
Sort By:
Journal of the National Cancer Institute
|
December 16, 1992
Rapid delivery of multiple high-dose chemotherapy courses with granulocyte colony-stimulating factor and peripheral blood-derived hematopoietic progenitor cells
J Crown, C Wassherheit, T Hakes, et al.
Cancer Investigation
|
January 1, 1991
Chemotherapy of metastatic Merkel cell cancer
J Crown, R Lipzstein, S Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 1995
Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer
A D Seidman, A Tiersten, C Hudis, et al.
Journal of Medical Screening
|
August 31, 2004
Surgical intervention in screen-detected patients versus symptomatic patients with breast cancer
M F Dillon, A D K Hill, C M Quinn, et al.
Frontiers in Psychiatry
|
February 23, 2026
Mental health and service utilization among cisgender-heterosexual, sexual minority, and gender minority autistic adults
Shalini Sivathasan, Mario J Crown, Elizabeth Rutenberg, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy
|
January 1, 1994
Phase I trial of intravenous and intraperitoneal administration of granulocyte-macrophage colony-stimulating factor
G C Toner, J L Gabrilove, M Gordon, et al.
British Journal of Cancer
|
May 27, 2015
Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells
F Caiazza, P M McGowan, M Mullooly, et al.
British Journal of Cancer
|
March 15, 2025
Correction: Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells
F Caiazza, P M McGowan, M Mullooly, et al.
International Journal of Cancer
|
September 13, 2016
Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
N C Synnott, A Murray, P M McGowan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 24, 2013
Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer
J Crown, M J Kennedy, P Tresca, et al.
Page
of 11
Search research articles
Search
Showing results (71-80 of 102) with videos related to
Sort By:
Page
of 11
Journal of the National Cancer Institute
|
December 16, 1992
Rapid delivery of multiple high-dose chemotherapy courses with granulocyte colony-stimulating factor and peripheral blood-derived hematopoietic progenitor cells
J Crown, C Wassherheit, T Hakes, et al.
Cancer Investigation
|
January 1, 1991
Chemotherapy of metastatic Merkel cell cancer
J Crown, R Lipzstein, S Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 1995
Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer
A D Seidman, A Tiersten, C Hudis, et al.
Journal of Medical Screening
|
August 31, 2004
Surgical intervention in screen-detected patients versus symptomatic patients with breast cancer
M F Dillon, A D K Hill, C M Quinn, et al.
Frontiers in Psychiatry
|
February 23, 2026
Mental health and service utilization among cisgender-heterosexual, sexual minority, and gender minority autistic adults
Shalini Sivathasan, Mario J Crown, Elizabeth Rutenberg, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy
|
January 1, 1994
Phase I trial of intravenous and intraperitoneal administration of granulocyte-macrophage colony-stimulating factor
G C Toner, J L Gabrilove, M Gordon, et al.
British Journal of Cancer
|
May 27, 2015
Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells
F Caiazza, P M McGowan, M Mullooly, et al.
British Journal of Cancer
|
March 15, 2025
Correction: Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells
F Caiazza, P M McGowan, M Mullooly, et al.
International Journal of Cancer
|
September 13, 2016
Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
N C Synnott, A Murray, P M McGowan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 24, 2013
Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer
J Crown, M J Kennedy, P Tresca, et al.
Page
of 11